We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Intuitive Surgical (ISRG) Upbeat on Q4 & 2017 Sales Results
Read MoreHide Full Article
Intuitive Surgical Inc. (ISRG - Free Report) recently announced better-than-expected preliminary net sales results for fourth-quarter and full-year 2017. The company is scheduled to report fourth-quarter 2017 results on Jan 25, 2018. Following the announcement, the stock closed at a value of $423.76 on Jan 10.
The company expects net sales for fourth-quarter 2017 to be approximately $892 million, up 18% on a year-over-year basis. The preliminary figure is higher than the Zacks Consensus Estimate of $845.7 million.
Full-year 2017 revenues are expected to be approximately $3.1 billion, up 16% on a year-over-year basis. The company’s preliminary figure compares favorably with the Zacks Consensus Estimate of $3.09 billion.
Preliminary fourth-quarter 2017 revenues of the instrument and accessories segment increased approximately 18% to $457 million on a year-over-year basis.
Per management, the anticipated revenue growth of the instruments and accessories segment is driven by da Vinci procedure growth.
The revenues from the da Vinci Surgical System is expected to be $$283 million, up 20% on a year-over-year basis. The company shipped 216 da Vinci Surgical Systems during the quarter.
The number of da Vinci surgeries rose approximately 17%, on a year-over-year basis in the fourth quarter. The upside can be attributed to the surge in,general surgery procedures in the United States and worldwide urologic procedures.
Service revenues increased approximately 13% to $153 million on a year-over-year basis.
Share Price Looks Up
Intuitive Surgical has had an outstanding performance on the bourses in the last year. The stock has gained 87.5%, outperforming the industry's rally of 27.2%.
Bio-Rad has a long-term growth rate of 25%. Over the last six months, the stock has rallied 10%, much above the industry’s gain of 5.8%.
Centene has a projected long-term growth rate of 14%. The stock has gained 28.3% over the last six months, much above the industry’s gain of 18.7%.
Magellan has an impressive expected growth rate of 28.4% for the first-quarter of 2018. The stock too gained 31% in the last six months and surpassed the broader industry.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Intuitive Surgical (ISRG) Upbeat on Q4 & 2017 Sales Results
Intuitive Surgical Inc. (ISRG - Free Report) recently announced better-than-expected preliminary net sales results for fourth-quarter and full-year 2017. The company is scheduled to report fourth-quarter 2017 results on Jan 25, 2018. Following the announcement, the stock closed at a value of $423.76 on Jan 10.
The company expects net sales for fourth-quarter 2017 to be approximately $892 million, up 18% on a year-over-year basis. The preliminary figure is higher than the Zacks Consensus Estimate of $845.7 million.
Full-year 2017 revenues are expected to be approximately $3.1 billion, up 16% on a year-over-year basis. The company’s preliminary figure compares favorably with the Zacks Consensus Estimate of $3.09 billion.
Intuitive Surgical, Inc. Price and Consensus
Intuitive Surgical, Inc. Price and Consensus | Intuitive Surgical, Inc. Quote
Preliminary fourth-quarter 2017 revenues of the instrument and accessories segment increased approximately 18% to $457 million on a year-over-year basis.
Per management, the anticipated revenue growth of the instruments and accessories segment is driven by da Vinci procedure growth.
The revenues from the da Vinci Surgical System is expected to be $$283 million, up 20% on a year-over-year basis. The company shipped 216 da Vinci Surgical Systems during the quarter.
The number of da Vinci surgeries rose approximately 17%, on a year-over-year basis in the fourth quarter. The upside can be attributed to the surge in,general surgery procedures in the United States and worldwide urologic procedures.
Service revenues increased approximately 13% to $153 million on a year-over-year basis.
Share Price Looks Up
Intuitive Surgical has had an outstanding performance on the bourses in the last year. The stock has gained 87.5%, outperforming the industry's rally of 27.2%.
Intuitive Surgical carries a Zacks Rank #2 (Buy).
Other top-ranked stocks in the broader medical space are Bio-Rad Laboratories Inc. (BIO - Free Report) , Centene Corporation (CNC - Free Report) and Magellan Health Inc. , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Bio-Rad has a long-term growth rate of 25%. Over the last six months, the stock has rallied 10%, much above the industry’s gain of 5.8%.
Centene has a projected long-term growth rate of 14%. The stock has gained 28.3% over the last six months, much above the industry’s gain of 18.7%.
Magellan has an impressive expected growth rate of 28.4% for the first-quarter of 2018. The stock too gained 31% in the last six months and surpassed the broader industry.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>